Terminology referring to the Seqirus (previously bioCSL) brand of trivalent influenza vaccine has been changed throughout the influenza chapter.
4.7.3 Epidemiology and 4.7.4 Vaccines
Most up-to-date information on influenza epidemiology (including Figure 4.7.1: Average annual influenza notification and hospitalisation rates for 2010 to 2013, Australia, by age group) and evidence on influenza vaccines added.
4.7.6 Dosage and administration
Information added on the appropriate action if a child aged 6 months to <3 years inadvertently receives a 0.5 mL dose of influenza vaccine, including in Table 4.7.1: Recommended doses of influenza vaccine.
Advice on the number of doses of annual influenza vaccine required for children aged 6 months to <9 years, based on their previous vaccination history, has been updated in Table 4.7.1: Recommended doses of influenza vaccine.
4.7.6 Dosage and administration and 4.7.7 Recommendations
Advice specifically on the use of quadrivalent influenza vaccine formulations has been included.
4.7.6 Dosage and administration and 4.7.10 Precautions
Information added on the co-administration of trivalent influenza vaccines and 13-valent pneumococcal conjugate vaccine in children.